Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Trial details
- Registry ID
- NCT05954143
- Phase
- Phase 2
The FDA approved Pertuzumab (Perjeta®) on 8 Jun 2012.
Drug identity checked against registry records
Also recorded as Perjeta®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast CancerNCT05954143 | BOLT | Phase 2 | Terminated | 2024-09-20Actual |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381 | Jazz Pharmaceuticals | Phase 2 | Recruiting | 2027-12-29Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2012-06-08Day | Pertuzumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125409", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["PERJETA"], "active_ingredients": ["PERTUZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20120608", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |